Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
R Donghi, … , G Della Porta, M A Pierotti
R Donghi, … , G Della Porta, M A Pierotti
Published April 1, 1993
Citation Information: J Clin Invest. 1993;91(4):1753-1760. https://doi.org/10.1172/JCI116385.
View: Text | PDF
Research Article Article has an altmetric score of 13

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

  • Text
  • PDF
Abstract

The p53 gene was analyzed in tumor specimens obtained from 52 patients with various types of carcinoma of the thyroid gland by a combined molecular and immunocytochemical approach. The histologic types included 37 well-differentiated papillary and follicular carcinomas, 8 poorly differentiated, and 7 undifferentiated carcinomas. The p53 gene was shown to be unaffected in all differentiated tumors by single-strand conformation polymorphism analysis. However, in two out of eight (25%) of poorly differentiated carcinomas and five out of seven (71%) undifferentiated carcinomas, p53 mutations were identified and subsequently characterized by DNA sequencing. One undifferentiated carcinoma displayed two areas with varying degrees of differentiation. The comparative analysis of the p53 gene, in both the more and the less differentiated area of this tumor, clearly showed that the p53 mutation was confined to the latter component of the tumor specimen. These results indicate that mutations of the p53 gene are associated with the most aggressive histologic types of thyroid tumors, such as the undifferentiated carcinoma and, to a certain extent, the poorly differentiated carcinoma, and that the alterations of this gene represent a late genetic event in human thyroid carcinogenesis.

Authors

R Donghi, A Longoni, S Pilotti, P Michieli, G Della Porta, M A Pierotti

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1980 Total
Citations: 2 2 3 2 6 7 6 5 13 11 6 12 17 4 14 7 7 11 13 7 8 9 9 11 10 13 8 12 8 14 6 9 1 273
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2016 (11)

Title and authors Publication Year
Genomic and Transcriptomic Hallmarks of Poorly-Differentiated and Anaplastic Thyroid Cancers
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A. Knauf, Ronak Shah, Snjezana Dogan, Julio Ricarte-Filho, Gnana P. Krishnamoorthy, Bin Xu, Nikolaus Schultz, Michael Berger, Chris Sander, Barry Taylor, Ronald Ghossein, Ian Ganly, James Fagin
Journal of Clinical Investigation 2016
Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer
S Narayanan, AD Colevas
Current Treatment Options in Oncology 2016
Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation
Y Shetzer, A Molchadsky, V Rotter
Cold Spring Harbor Perspectives in Medicine 2016
Expression of glutamine metabolism-related proteins in thyroid cancer
HM Kim, YK Lee, JS Koo
Oncotarget 2016
Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer
S Latteyer, V Tiedje, K König, S Ting, LC Heukamp, L Meder, KW Schmid, D Führer, LC Moeller
Endocrine 2016
Molecular genetics of thyroid cancer
M Rebaї, A Rebaї
Genetics Research 2016
Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
L Zhang, M Boufraqech, R Lake, E Kebebew
Oncotarget 2016
Nodular thyroid disease in the elderly: novel molecular approaches for the diagnosis of malignancy
S Sorrenti, E Baldini, F Tartaglia, A Catania, S Arcieri, D Pironi, PG Calò, A Filippini, S Ulisse
Aging clinical and experimental research 2016
Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer
S Latteyer, V Tiedje, K König, S Ting, LC Heukamp, L Meder, KW Schmid, D Führer, LC Moeller
Endocrine 2016
Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma
QX Wang, ED Chen, YF Cai, YL Zhou, ZC Zheng, YH Wang, YX Jin, WX Jin, XH Zhang, OC Wang
OncoTargets and therapy 2016
Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma
J Lu, S Guan, Y Zhao, Y Yu, Y Wang, Y Shi, X Mao, KL Yang, W Sun, X Xu, JS Yi, T Yang, J Yang, JG Nuchtern
Oncotarget 2016

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Referenced in 2 patents
Referenced in 1 clinical guideline sources
55 readers on Mendeley
See more details